Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of medical device builder Boston Scientific
So what: Second-quarter non-GAAP earnings of $0.17 per share were 42% above the year-ago quarter and above management guidance for the period, helped by new product introductions and a strong performance by the neuromodulation division. The company also extended its share buyback program by a cool $1 billion and started to pay back some of its more than $4 billion in long-term debt out of strong cash flows.
Now what: Foolish health care champion Brian Orelli recently called Boston Scientific a "show-me company," and I think the company is showing us plenty right now. Though swooning a bit over the last three months, the stock has outperformed the market as well as close rivals Johnson & Johnson
Interested in more info on Boston Scientific? Add it to your watchlist.